The prospect of repurposing PDE5 inhibitors for the treatment of neurodegenerative diseases, including Alzheimer’s disease, has recently garnered considerable interest [4]. The gene discussed is PDE5A; the disease is early-onset autosomal dominant Alzheimer disease.